Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Molecular dynamics study of HIV-1 RT-DNA-nevirapine complexes explains NNRTI inhibition and resistance by connection mutations.

Vijayan RS, Arnold E, Das K.

Proteins. 2014 May;82(5):815-29. doi: 10.1002/prot.24460. Epub 2013 Nov 22.

2.

The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.

Schuckmann MM, Marchand B, Hachiya A, Kodama EN, Kirby KA, Singh K, Sarafianos SG.

J Biol Chem. 2010 Dec 3;285(49):38700-9. doi: 10.1074/jbc.M110.153783. Epub 2010 Sep 27.

3.

Compensatory role of double mutation N348I/M184V on nevirapine binding landscape: insight from molecular dynamics simulation.

Karubiu W, Bhakat S, Soliman ME.

Protein J. 2014 Oct;33(5):432-46. doi: 10.1007/s10930-014-9576-8.

PMID:
25107349
4.

N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.

Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, Wynhoven B, Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G.

PLoS Med. 2007 Dec;4(12):e335.

5.

Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.

Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, Petropoulos CJ.

Antimicrob Agents Chemother. 2010 May;54(5):1973-80. doi: 10.1128/AAC.00870-09. Epub 2010 Mar 1.

6.

N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.

Biondi MJ, Beilhartz GL, McCormick S, Götte M.

J Biol Chem. 2010 Aug 27;285(35):26966-75. doi: 10.1074/jbc.M110.105775. Epub 2010 Jun 8.

7.

HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.

Menéndez-Arias L, Betancor G, Matamoros T.

Antiviral Res. 2011 Nov;92(2):139-49. doi: 10.1016/j.antiviral.2011.08.020. Epub 2011 Aug 28. Review.

PMID:
21896288
8.

A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Nikolenko GN, Delviks-Frankenberry KA, Pathak VK.

J Virol. 2010 May;84(10):5238-49. doi: 10.1128/JVI.01545-09. Epub 2010 Mar 10.

9.

Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.

Ren J, Nichols CE, Stamp A, Chamberlain PP, Ferris R, Weaver KL, Short SA, Stammers DK.

FEBS J. 2006 Aug;273(16):3850-60.

10.

Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Hachiya A, Kodama EN, Sarafianos SG, Schuckmann MM, Sakagami Y, Matsuoka M, Takiguchi M, Gatanaga H, Oka S.

J Virol. 2008 Apr;82(7):3261-70. doi: 10.1128/JVI.01154-07. Epub 2008 Jan 23.

11.

Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis.

Betancor G, Álvarez M, Marcelli B, Andrés C, Martínez MA, Menéndez-Arias L.

Nucleic Acids Res. 2015 Feb 27;43(4):2259-70. doi: 10.1093/nar/gkv077. Epub 2015 Feb 6.

12.

HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors.

Hachiya A, Marchand B, Kirby KA, Michailidis E, Tu X, Palczewski K, Ong YT, Li Z, Griffin DT, Schuckmann MM, Tanuma J, Oka S, Singh K, Kodama EN, Sarafianos SG.

J Biol Chem. 2012 Aug 24;287(35):29988-99. doi: 10.1074/jbc.M112.351551. Epub 2012 Jul 2.

13.

The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.

Xu HT, Colby-Germinario SP, Oliveira M, Han Y, Quan Y, Zanichelli V, Wainberg MA.

J Virol. 2014 Feb;88(3):1536-47. doi: 10.1128/JVI.02904-13. Epub 2013 Nov 13.

14.

Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.

Zhou Z, Madrid M, Evanseck JD, Madura JD.

J Am Chem Soc. 2005 Dec 14;127(49):17253-60.

PMID:
16332074
15.

A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.

Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Bánhegyi D, Clotet B, Lundgren J, Menéndez-Arias L, Martinez-Picado J; EuroSIDA Study Group.

J Infect Dis. 2011 Sep 1;204(5):741-52. doi: 10.1093/infdis/jir385.

PMID:
21844300
16.

Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.

Michailidis E, Singh K, Ryan EM, Hachiya A, Ong YT, Kirby KA, Marchand B, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG.

Cell Mol Biol (Noisy-le-grand). 2012 Dec 22;58(1):187-95.

17.

HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.

Das K, Arnold E.

Curr Opin Virol. 2013 Apr;3(2):119-28. doi: 10.1016/j.coviro.2013.03.014. Epub 2013 Apr 19. Review.

18.

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity.

Wright DW, Deuzing IP, Flandre P, van den Eede P, Govaert M, Setiawan L, Coveney PV, Marcelin AG, Calvez V, Boucher CA, Beerens N.

PLoS One. 2013 Oct 2;8(10):e74078. doi: 10.1371/journal.pone.0074078. eCollection 2013.

19.

Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.

Balzarini J.

Curr Top Med Chem. 2004;4(9):921-44. Review. Erratum in: Curr Top Med Chem. 2004;4(16):1825.

PMID:
15134549
20.

Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.

Alcaro S, Alteri C, Artese A, Ceccherini-Silberstein F, Costa G, Ortuso F, Bertoli A, Forbici F, Santoro MM, Parrotta L, Flandre P, Masquelier B, Descamps D, Calvez V, Marcelin AG, Perno CF, Sing T, Svicher V.

ChemMedChem. 2011 Dec 9;6(12):2203-13. doi: 10.1002/cmdc.201100362. Epub 2011 Sep 27.

PMID:
21953939

Supplemental Content

Support Center